Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Taha Sen, Hiddo J.L. Heerspink
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 732-739
Open Access | Times Cited: 111

Showing 1-25 of 111 citing articles:

Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Kunihiro Matsushita, Shoshana H. Ballew, Angela Yee‐Moon Wang, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 11, pp. 696-707
Closed Access | Times Cited: 326
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, et al.
Kidney International (2021) Vol. 100, Iss. 1, pp. 215-224
Open Access | Times Cited: 279
Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 169
Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies
Hao Wu, Romer Gonzalez Villalobos, Xiang Yao, et al.
Cell Metabolism (2022) Vol. 34, Iss. 7, pp. 1064-1078.e6
Open Access | Times Cited: 144
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 114
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
Xinyu Zhao, Shuangshuang Li, Ying-xin He, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1328-1340
Closed Access | Times Cited: 51
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, et al.
The Lancet Diabetes & Endocrinology (2023) Vol. 12, Iss. 1, pp. 51-60
Open Access | Times Cited: 41
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Comparison of Effectiveness Among Different Sodium‐Glucose Cotransoporter‐2 Inhibitors According to Underlying Conditions: A Network Meta‐Analysis of Randomized Controlled Trials
Ryoma Kani, Atsuyuki Watanabe, Yoshihisa Miyamoto, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 16
Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients
Thomas Ebert, Ognian Neytchev, Anna Witasp, et al.
Antioxidants and Redox Signaling (2021) Vol. 35, Iss. 17, pp. 1426-1448
Open Access | Times Cited: 96
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
Science (2021) Vol. 373, Iss. 6554, pp. 522-527
Closed Access | Times Cited: 66
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes
Priya Vart, Muthiah Vaduganathan, Niels Jongs, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 12, pp. 1754-1762
Open Access | Times Cited: 43
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials
Hiddo J.L. Heerspink, Priya Vart, Niels Jongs, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3327-3336
Closed Access | Times Cited: 30
The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
Antonio Ceriello, Giuseppe Lucisano, Francesco Prattichizzo, et al.
The Lancet Regional Health - Europe (2023) Vol. 31, pp. 100666-100666
Open Access | Times Cited: 22
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 10
From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 51
The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
Michele Provenzano, Niels Jongs, Priya Vart, et al.
Kidney International Reports (2021) Vol. 7, Iss. 3, pp. 436-443
Open Access | Times Cited: 51
SGLT-2 inhibitors as cardio-renal protective agents
Irene Caruso, Francesco Giorgino
Metabolism (2021) Vol. 127, pp. 154937-154937
Closed Access | Times Cited: 41
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Akihiko Koshino, Meir Schechter, Taha Sen, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2644-2652
Open Access | Times Cited: 31
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Huijing Wang, Ting Li, Fangfang Sun, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002686-e002686
Open Access | Times Cited: 29
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Giulia Bendotti, Laura Montefusco, Ida Pastore, et al.
Journal of Endocrinological Investigation (2023) Vol. 46, Iss. 12, pp. 2445-2452
Closed Access | Times Cited: 18
Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials
Ernesto Maddaloni, Ilaria Cavallari, Ylenia La Porta, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 5, pp. 1341-1350
Closed Access | Times Cited: 17
Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study
Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 6, pp. 1758-1768
Open Access | Times Cited: 16
Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors
Marcus D. Säemann, Andreas Kronbichler
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 5, pp. 614-617
Closed Access | Times Cited: 36
Expectations in children with glomerular diseases from SGLT2 inhibitors
Luigi Cirillo, Fiammetta Ravaglia, Carmela Errichiello, et al.
Pediatric Nephrology (2022) Vol. 37, Iss. 12, pp. 2997-3008
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top